Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Spleen tyrosine kinase (SYK) inhibitor =Preliminary data= ==CLL== # Sharman...") |
Warner-admin (talk | contribs) m (Text replacement - "9 PubMed" to "9/ PubMed") |
||
(10 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
Spleen tyrosine kinase (SYK) inhibitor | Spleen tyrosine kinase (SYK) inhibitor | ||
− | =Preliminary data= | + | ==Preliminary data== |
− | ==[[ | + | ===[[Chronic lymphocytic leukemia]]=== |
− | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [ | + | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/25696919/ PubMed] |
− | + | ==Also known as== | |
− | [[Category: | + | *'''Code name:''' GS-9973 |
− | [[Category:Oral | + | |
+ | [[Category:Drugs]] | ||
+ | |||
+ | [[Category:Oral medications]] | ||
− | |||
[[Category:SYK inhibitors]] | [[Category:SYK inhibitors]] | ||
− | [[Category:Investigational]] | + | [[Category:Chronic lymphocytic leukemia medications (investigational)]] |
+ | [[Category:Investigational drugs]] |
Latest revision as of 00:13, 7 May 2023
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
Chronic lymphocytic leukemia
- Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed
Also known as
- Code name: GS-9973